LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
16 août 2021 07h05 HE
|
Lava Therapeutics N.V.
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant...
LAVA Therapeutics宣布任命Amy Garabedian为总法律顾问兼公司秘书
28 juil. 2021 08h28 HE
|
Lava Therapeutics N.V.
荷兰乌得勒支和费城, July 28, 2021 (GLOBE NEWSWIRE) -- 专注于开发双特异性γ-δ T细胞衔接抗体以改变癌症治疗的临床阶段生物技术公司LAVA Therapeutics N.V.（Nasdaq: LVTX）今天宣布，任命Amy Garabedian为总法律顾问兼公司秘书。Garabedian女士是位经验丰富的领导者，在生命科学行业拥有广泛的企业和事务专业知识。 ...
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
27 juil. 2021 08h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific...
LAVA Therapeutics宣布在LAVA-051治疗多种血液系统恶性肿瘤的1/2a期临床试验开始首位患者给药
13 juil. 2021 08h56 HE
|
Lava Therapeutics N.V.
荷兰乌得勒支和费城, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics NV（纳斯达克股票代码：LVTX）是一家专注于开发双特异性γ-δ T细胞衔接抗体（bsTCE）以改变癌症治疗方式的生物技术公司。该公司今天宣布，其针对复发性和/或难治性慢性淋巴细胞白血病（CLL）、多发性骨髓瘤（MM）和急性髓系白血病（AML）患者的LAVA-051...
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
13 juil. 2021 07h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on developing bispecific gamma-delta T cell...
LAVA Therapeutics将参加2021年Jefferies医疗保健虚拟大会
25 mai 2021 07h51 HE
|
LAVA Therapeutics BV
荷兰乌得勒支和费城, May 25, 2021 (GLOBE NEWSWIRE) -- 专注于运用其双特异性γ-δ T细胞结合物专业知识来改变癌症疗法的生物技术公司LAVA Therapeutics N.V.（纳斯达克代码：LVTX）今天宣布，其首席执行官Stephen Hurly将出席美国东部时间2021年6月1日星期二上午11:30举行的2021年Jefferies医疗保健 虚拟大会。 ...
LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
25 mai 2021 06h30 HE
|
LAVA Therapeutics BV
UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta...
LAVA Therapeutics提供企业更新信息并报告第一季度财务业绩
20 mai 2021 10h46 HE
|
LAVA Therapeutics BV
IPO将现金和现金等价物的资产负债表增加到1.6亿美元；预计将可为至少2023年下半年以前的运营提供资金 血液和实体肿瘤项目的临床开发计划在按计划进行 通过关键管理和董事会任命加强了领导能力 荷兰乌得勒支和美国费城, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics...
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
20 mai 2021 06h30 HE
|
LAVA Therapeutics BV
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both...
LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
18 mai 2021 06h30 HE
|
LAVA Therapeutics BV
UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta...